You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 117 No. 1, January 1982 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Clinical Correlations With Drug Sensitivities in the Clonogenic Assay

A Retrospective Study

Barry D. Mann, MD; David H. Kern, PhD; Armando E. Giuliano, MD; Martyn W. Burk, MD, PhD; Mary Ann Campbell; Larry R. Kaiser, MD; Donald L. Morton, MD

Arch Surg. 1982;117(1):33-36.


Abstract

• We tested the ability of the in vitro clonogenic assay (CLAS) to predict clinical response for patients with solid tumors. Patients had objectively measurable disease and received at least one course of chemotherapy. The correlation between clinical responses and in vitro sensitivity was evaluated retrospectively. Tumor types included melanoma (19), sarcoma (five), hepatoma (one), and carcinoma of the stomach (two), colon (three), lung (one), and breast (one). Five patients received two separate courses of chemotherapy with different drugs or drug regimens. In nine of 11 (82%) instances, tumors were sensitive to a particular drug, and the patient had at least 50% regression of tumor following treatment with the tested drug. Two patients whose tumors were sensitive in vitro had no evidence of clinical response. In 25 of 26 assays, the CLAS accurately predicted tumor resistance, and only one patient had evidence of clinical response (96%). Associations of in vitro results with clinical responses were highly significant. The CLAS can accurately predict the chemosensitivity of a variety of solid tumors.

(Arch Surg 1982;117:33-36)



Author Affiliations

From the Division of Oncology, Department of Surgery, UCLA School of Medicine (Drs Mann, Kern, Giuliano, Burk, Kaiser, and Morton); and the Surgical Service, Sepulveda Veterans Administration Hospital, Sepulveda, Calif (Drs Kern, Giuliano, Burk, and Morton and Ms Campbell).


Footnotes

Accepted for publication July 9, 1981.

Read at the annual meeting of the Southern California Chapter of the American College of Surgeons, Santa Barbara, Calif, Jan 24, 1981.

Reprint requests to Division of Surgical Oncology, Factor Building, UCLA School of Medicine, Los Angeles, CA 90024 (Dr Mann).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Objective Criteria for In-vitro Responses in Human Tumor Colony-forming Assays
Koziol et al.
Med Decis Making 1988;8:304-309.
ABSTRACT  

Heterogeneity of Human Metastatic Clones by In Vitro Chemosensitivity Testing: Implications for the Clinical Application of the Clonogenic Assay
Bertelsen et al.
Arch Surg 1983;118:1406-1409.
ABSTRACT  

Biopsy of Thoracic Neoplasms for Assay of Chemosensitivity: New Indication for Thoracotomy
Bertelsen et al.
Arch Surg 1983;118:1074-1076.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1982 American Medical Association. All Rights Reserved.